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Abstract
Cerebellar granule neurons are the most abundant neurons in the brain, and a critical element of
the circuitry that controls motor coordination and learning. In addition, granule neuron precursors
(GNPs) are thought to represent cells of origin for medulloblastoma, the most common malignant
brain tumor in children. Thus, understanding the signals that control the growth and differentiation
of these cells has important implications for neurobiology and neuro-oncology. Our previous
studies have shown that proliferation of GNPs is regulated by Sonic hedgehog (Shh), and that
aberrant activation of the Shh pathway can lead to medulloblastoma. Moreover, we have
demonstrated that Shh-dependent proliferation of GNPs and medulloblastoma cells can be blocked
by basic fibroblast growth factor (bFGF). But while the mitogenic effects of Shh signaling have
been confirmed in vivo, the inhibitory effects of bFGF have primarily been studied in culture.
Here we demonstrate that mice lacking FGF signaling in GNPs exhibit no discernable changes in
GNP proliferation or differentiation. In contrast, activation of FGF signaling has a potent effect on
tumor growth: treatment of medulloblastoma cells with bFGF prevents them from forming tumors
following transplantation, and inoculation of tumor-bearing mice with bFGF markedly inhibits
tumor growth in vivo. These results suggest that activators of FGF signaling may be useful for
targeting medulloblastoma and other Shh-dependent tumors.
INTRODUCTION
Normal development requires a delicate balance between proliferation and differentiation.
Too little proliferation can result in impaired tissue structure and function, while excessive
proliferation can lead to cancer. One salient example of this is the development of granule
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neurons in the cerebellum. Mutant mice that fail to generate enough granule cells develop
severe ataxia (1-3), and patients with congenital granule cell degeneration have deficits in
motor coordination, language use, and cognitive function (4). Conversely, when GNP
differentiation fails, cells that would normally become post-mitotic continue to proliferate
and give rise to medulloblastoma (5, 6). Thus, elucidating the molecular mechanisms that
control growth and differentiation of granule neurons is critical for understanding both
normal cerebellar development and tumorigenesis.
GNPs are generated on the surface of the cerebellum in a structure called the external
germinal layer (EGL) (7, 8). At birth, the EGL contains a single layer of undifferentiated
cells, but over the next few days, these cells undergo extensive proliferation to generate a
large pool of GNPs (9, 10). As new GNPs are generated, older cells exit the cell cycle and
differentiate, and their cell bodies migrate inward to the internal granule layer (IGL) (11,
12). The waves of proliferation and differentiation continue until about 3 weeks of age (in
mice), when all GNPs mature into granule neurons and the EGL disappears (13).
Studies from our lab and others have demonstrated that the major mitogen for GNPs is Sonic
hedgehog (Shh) (14-16). Produced by Purkinje neurons, Shh acts by binding to the
transmembrane protein Patched (Ptc). In the absence of Shh, Ptc acts as an antagonist of the
hedgehog pathway, inhibiting the function of the signal transducing protein Smoothened
(Smo). When Shh binds to Ptc, inhibition is alleviated, and Smo initiates a signaling cascade
that results in activation of Gli family transcription factors and expression of hedgehog
target genes (17, 18). In GNPs, these include N-myc and cyclins D1 and D2 (19, 20), and
thus Shh signaling results in a robust proliferative response. Notably, mice with targeted
mutations that impair Shh signaling (e.g. deletion of Shh, Smo or Gli2) exhibit decreased
GNP proliferation (21-23); conversely, animals with mutations that activate the pathway
(e.g. deletion of ptc) develop medulloblastoma (5, 6, 24-26). The fact that ~30% of human
medulloblastomas contain activating mutations in the Shh pathway (27-29) also implies a
key role for this pathway in proliferation and tumorigenesis.
But while the importance of Shh in GNP proliferation is well established, the signals that
cause GNPs to exit the cell cycle and differentiate remain much less clear. One potential
explanation might be decreased exposure of GNPs to Shh ligand. However, previous studies
have shown that Shh continues to be expressed by Purkinje cells into adulthood (30). The
fact that GNPs can exit the cell cycle despite the continued presence of Shh suggests that
some other signal may override the mitogenic effects of Shh. We have previously shown
that bFGF can block proliferation and promote differentiation of GNPs in the presence of
Shh (14, 31), raising the possibility that FGFs might serve as differentiation factors for these
cells. In addition, we have shown that bFGF can inhibit the growth of tumor cells from ptc
mutant mice (31), suggesting that this pathway may hold promise for medulloblastoma
therapy.
Although FGFs have been shown to inhibit proliferation of GNPs and tumor cells in vitro,
their effects on these cells have not been rigorously tested in vivo. In the current study, we
used conditional knockout mice to investigate the importance of FGF signaling in GNP
development in vivo, and intratumoral injections to test the efficacy of bFGF as a treatment
for medulloblastoma. Our results suggest that genetic ablation of FGFRs does not alter GNP
differentiation in vivo. However, exposure of medulloblastoma cells to bFGF dramatically
inhibits their growth. Thus, while bFGF may not be critical for GNP development,
activation of the FGF pathway may be useful in the treatment of Shh-dependent tumors.
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FGF inhibits proliferation of GNPs during postnatal development
GNPs undergo proliferation and differentiation in the EGL during the first 2-3 weeks after
birth. Our previous studies (31) have shown that bFGF inhibits proliferation and promotes
differentiation of GNPs. To determine whether the inhibitory effects of bFGF are age-
dependent, we isolated GNPs at a range of postnatal ages and measured incorporation of
tritiated thymidine in response to Shh and bFGF. Consistent with our previous observations,
P7 GNPs proliferated robustly in response to Shh, and this response was abolished by
addition of bFGF (Figure 1C). Marked inhibition of Shh-induced proliferation was also seen
at P2, P4 and P11 (Figures 1A, B and D). Thus, bFGF can inhibit proliferation of GNPs
throughout postnatal development.
bFGF promotes cell cycle exit and acts downstream of Suppressor of Fused
Our previous studies suggested that bFGF promotes cell cycle exit of GNPs and accelerates
their differentiation into granule neurons (31). To better understand the mechanisms by
which bFGF inhibits proliferation, we performed cell cycle analysis on cells treated with
Shh ± bFGF. As shown in Supplementary Figure 1A-C, in the absence of growth factors the
majority of GNPs exit the cell cycle within 48 hours (< 2% of cells in S, G2 and M phases of
the cell cycle). Treatment with Shh maintains a population of GNPs in cycle (~11% of cells
in S/G2/M). However, co-treatment with bFGF inhibits the effects of Shh and causes cells to
accumulate in the G0/G1 phase of the cell cycle (~2% of cells in S/G2/M). We also
examined whether bFGF increased apoptosis by staining cells with antibodies specific for
cleaved caspase 3. As shown in Supplementary Figure 2A, bFGF did not cause a significant
increase in apoptosis. Together, these data suggest that bFGF acts by promoting cell cycle
exit and differentiation rather than by inducing cell death.
We previously showed that bFGF can inhibit proliferation of GNPs in response to
stimulation with Shh ligand, as well as of tumor cells resulting from mutations in patched
(31). These data suggest that bFGF acts on the Shh pathway at a level downstream of
patched. To gain further insight into the mechanisms by which bFGF interferes with Shh
signaling, we tested the effects of bFGF on cells in which the Shh pathway is activated as a
consequence of a Smo mutation. NeuroD2-SmoA1 transgenic mice exhibit increased Shh
pathway activation and proliferation of GNPs and develop medulloblastoma (32). As shown
in Supplementary Figure 3A, we found that bFGF inhibits the basal proliferation of these
cells, suggesting that it acts downstream of Smo.
Shh target genes can also be activated by mutations in Suppressor of Fused (Sufu), a
negative regulator of the pathway that regulates processing, localization and transcriptional
activity of Gli proteins (33-35). To determine whether bFGF could suppress activation of the
pathway resulting from loss of Sufu, we tested the effects of bFGF on mouse embryo
fibroblasts (MEFs) from Sufu-deficient mice (36). As shown in Supplementary Figure 3B,
Sufu−/− MEFs exhibit constitutive expression of gli1 that is significantly higher than that
seen in wild type MEFs. Importantly, addition of bFGF to Sufu−/− MEFS results in a 3-fold
reduction in gli1 expression, suggesting that bFGF can inhibit activation of the pathway
mediated by loss of Sufu. Similar results were observed when a Gli-luciferase reporter gene
was used to monitor gli1 expression (data not shown). Together these data suggest that
bFGF inhibits Shh signaling at a level downstream of Smo and Sufu, and proximal to the
nucleus.
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The inhibitory effects of bFGF are mediated by FGFR1
The FGF receptor family consists of four members (FGFR1-4), three of which can undergo
alternative splicing to generate multiple receptor isoforms (FGFR4 exists in only one
isoform) (37). To determine which receptors might mediate inhibition of Shh signaling and
proliferation, we first examined the receptors expressed by GNPs. Cells were FACS-sorted
from the cerebellum of Math1-GFP transgenic mice (which express green fluorescent
protein (GFP) in their GNPs (38, 39)), and RNA was isolated and subjected to RT-PCR
using primers for FGFR receptor isoforms. Consistent with previous studies (40), we found
that GNPs express FGFR1, 2 and 4; FGFR3 was also detected in some samples, but usually
at lower levels than the other receptors (Figure 2A).
We have previously shown that FGF-mediated inhibition of Shh signaling can be blocked by
pharmacological antagonists of FGFR kinase activity (31). Because these antagonists can act
on all FGF receptors, the particular receptor or receptors required for inhibition of hedgehog
signaling remained unclear. To determine which FGFRs were required for the inhibitory
effects of bFGF in GNPs, we used mice lacking FGFR1, 2 and 4, the predominant FGFRs
expressed in these cells. Complete loss of FGFR1 or FGFR2 results in embryonic lethality
(41, 42); therefore we crossed mice carrying loxP-flanked alleles of these genes (43, 44)
with Math1-Cre transgenic mice (5, 6) to generate animals lacking FGFR1 or FGFR2 in
GNPs. These animals, along with germline FGFR4 knockout mice (which remain viable into
adulthood (45, 46)), were used to examine the effects of loss of FGFRs on GNP responses to
Shh and bFGF. GNPs from single knockout mice were cultured in the presence of Shh ±
bFGF for 48 hours and then assayed for incorporation of tritiated thymidine. As shown in
Figure 2B-D, GNPs from mice lacking FGFR1, FGFR2 or FGFR4 all showed robust
proliferation in response to Shh. But while loss of FGFR2 or FGFR4 did not affect FGF-
mediated inhibition of Shh-induced proliferation (Figure 2 C-D), loss of FGFR1 completely
abrogated the inhibitory effects of bFGF (Figure 2B). Consistent with its inability to
suppress Shh-induced proliferation, bFGF was also unable to inhibit Shh induction of gli1 in
FGFR1-deficient GNPs (Supplementary Figure 4). FGFR1-deficient GNPs treated with Shh
also showed no change in cell cycle distribution following exposure to bFGF
(Supplementary Figure 1D-F). Together, these data indicate that the inhibitory effects of
bFGF require signaling through FGFR1.
Our previous studies (31) demonstrated that FGF-mediated inhibition of Shh signaling is
mediated, at least in part, by activation of the extracellular signal-regulated kinase (ERK).
To determine whether GNPs lacking FGFR1 were still capable of activating this kinase, we
stimulated cells with bFGF and examined the phosphorylation status of ERK. As shown in
Supplementary Figure 5, wild type (WT) GNPs exhibited robust ERK phosphorylation in
response to bFGF. In contrast, GNPs from mice lacking FGFR1 showed no increase in ERK
phosphorylation. These studies suggest that loss of FGFR1 renders GNPs unresponsive to
bFGF.
FGF signaling is not required for GNP differentiation
Since our studies indicated that FGFR1 was a key mediator of FGF-mediated inhibition in
vitro, we next examined the effects of loss of FGFR1 on GNP differentiation in vivo. We
isolated cerebella from WT and FGFR1-deficient mice at P7 and stained them with
antibodies specific for markers of proliferation and differentiation. As shown in Figure 3A,
WT cerebella contained a broad band of proliferating (Ki67+) cells in the outer EGL and
discrete regions of differentiating (NeuN+) granule neurons in the inner EGL and IGL.
Surprisingly, expression of Ki67 and NeuN in FGFR1 knockout mice was indistinguishable
from that seen in WT littermates (Figure 3B). These results suggested that loss of FGFR1
does not impair GNP cell cycle exit or differentiation.
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One possible explanation for the lack of an in vivo phenotype in FGFR1-deficient mice was
compensation by other FGFR receptors. To address this possibility, we generated triple
knockout (TKO) mice lacking FGFRs 1, 2 and 4 in GNPs. Similar to GNPs from FGFR1
knockout mice, Shh-induced proliferation of GNPs from TKO mice was not inhibited by
bFGF in culture (Supplementary Figure 6), nor did TKO GNPs treated with bFGF exhibit an
increase in apoptosis (Supplementary Figure 2B). In contrast, BMP2, which inhibits GNP
proliferation through a distinct mechanism (47, 48)) remained capable of inhibiting Shh-
induced proliferation of TKO GNPs (Supplementary Figure 6). However, analysis of TKO
cerebella showed no significant differences in proliferation or differentiation when
compared to WT littermates (Figure 3C-D). Similar results were seen when cerebella were
analyzed at P2, P4, P11 and P14 (data not shown). Based on these findings we conclude that
FGF signaling, while capable of promoting differentiation in vitro, is not required for GNP
differentiation in vivo.
FGF inhibits growth of medulloblastoma cells in vitro and in vivo
While the above experiments suggest that FGF signaling is not essential for GNP
development, they leave open the possibility that it might be useful as a treatment for Shh-
dependent tumors. Recent studies from our lab have indicated that tumors from ptc+/−
mutant mice are propagated by a subpopulation of tumor cells that expresses the
carbohydrate antigen CD15/SSEA-1 (49). To determine whether CD15+ cells are sensitive
to FGF-mediated inhibition, we purified these cells by flow cytometry, cultured them in the
presence or absence of bFGF, and then measured their incorporation of tritiated thymidine.
As shown in Figure 4A, bFGF markedly inhibited the growth of both unfractionated and
CD15+ tumor cells. The basal proliferation of CD15− cells was much lower than their CD15
counterparts, but these cells were inhibited by bFGF as well. Moreover, we did not see an
increase in apoptosis when unsorted tumor cells from ptc+/− mice were cultured in the
presence of bFGF, indicating that the reduced proliferation observed following bFGF
treatment was not due to increased cell death (Supplementary Figure 7). These results
indicated that tumor-propagating cells from ptc+/− mice are sensitive to the inhibitory effects
of bFGF.
Although bFGF inhibited the growth of tumor cells, it was possible that this inhibition was
transient, or that a subpopulation of tumor cells remained capable of forming tumors even
after exposure to bFGF. To test this possibility, we isolated tumor cells from ptc+/− mice and
cultured them in the presence or absence of bFGF for 24hr. Cells were then transplanted into
the cerebellum of SCID-beige mice and recipients were monitored for symptoms of tumor
development (Figure 4B). As shown in Figure 4C, 93% of mice that received tumor cells
cultured in control media went on to form tumors. In contrast, no tumors resulted from
transplantation of FGF-treated cells. These studies demonstrated that the growth-inhibitory
effects of bFGF are not transient, but rather, result in a long-lasting inability of cells to form
tumors in vivo.
Having shown that bFGF pretreatment could abolish the tumorigenic potential of ptc+/−
medulloblastoma cells, we wondered whether bFGF could also inhibit the expansion of
tumor cells that were already growing in animals. To test this, we transplanted tumor cells
into the cerebellum of SCID-beige mice, and after 8-12 days, injected PBS (vehicle) or
bFGF into the implantation site. Animals received an additional injection 3-5 days later, and
were then monitored for signs of tumor development (Figure 5A). For these experiments, we
used tumors from Math1-GFP;ptc+/− mice, which allowed us to detect tumor bulk based on
GFP expression (50). As shown in Figure 5B, tumors injected with PBS typically grew
unchecked, encompassing a large portion of the cerebellum. In contrast, bFGF-treated
tumors were barely detectable in intact cerebella (Figure 5C). Analysis of cerebellar sections
revealed large numbers of GFP+ cells in PBS-treated animals, and few such cells in animals
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treated with bFGF (Figure 5D-G). H&E staining confirmed that the area of each tumor was
comparable to the expression of GFP, both in the control and bFGF-treated animals
(Supplementary Figure 8). To quantitate the reduction in tumor size following FGF
treatment, we counted the number of sections in which tumor cells could be found. As
shown in Figure 5H, FGF treatment resulted in a significant reduction in tumor bulk. Based
on these results, we conclude that FGF is a potent inhibitor of tumor growth and may be
useful for targeting ptc+/− mutant medulloblastomas and other hedgehog-dependent tumors.
The studies described above reinforce our previous observations that bFGF can inhibit Shh
signaling and Shh-induced proliferation in GNPs and tumor cells. Moreover, they provide
new insight into mechanisms of bFGF-mediated inhibition, demonstrating that (1) this
requires signaling through FGFR1 and (2) that it acts on the Shh pathway at a level
downstream of Smo and Sufu. Interestingly, a recent report (Lauth et al., 2010) demonstrates
that oncogenic Ras can also inhibit Shh signaling, and that this involves activation of the
DYRK1B kinase. Since bFGF signaling is likely to involve activation of Ras, it is tempting
to speculate that bFGF-mediated inhibition involves a similar mechanism. However, it is
notable that oncogenic Ras and Dyrk1B did not affect signaling in Sufu−/− cells, suggesting
that the mechanisms underlying inhibition, while they might overlap with those associated
with bFGF, are likely distinct.
Notwithstanding the potent inhibitory effects of bFGF in vitro, our studies demonstrate that
FGF signaling is not required for normal GNP development. The fact that mice lacking FGF
receptors showed no obvious phenotype is surprising, given the marked anti-mitogenic
effects of FGF signaling for these cells in vitro. One possible explanation for this is that
some level of FGF signaling persists even in the absence of FGF receptors. FGFs are known
to activate transcription of Sprouty genes, which function as negative regulators of signaling
by FGFRs and other receptor tyrosine kinases (51). In the absence of FGF signaling, this
negative feedback loop could be lost, resulting in a compensatory increase in activation of
the FGF pathway. Alternatively, it is possible that other extracellular signals may act
independently to promote cell cycle exit and differentiation of GNPs in the postnatal
cerebellum. In this regard, it is worth noting that in addition to bFGF, vitronectin, pituitary
adenylate cyclase activating polypeptide (PACAP) and bone morphogenetic proteins
(BMPs) 2 and 4 have all been reported to inhibit Shh-induced proliferation of GNPs in vitro
(47, 48, 52, 53). To date, none of these have been shown to be required for GNP
differentiation in vivo. Thus, the signals responsible for GNP cell cycle exit and
differentiation remain unclear, and the possibility that multiple factors cooperate to regulate
these processes remains open.
Whatever its role in GNP development, our studies clearly indicate that FGF signaling can
inhibit the growth of GNP-derived tumors. This is significant for several reasons. First, it
highlights the unique characteristics of the tumor-propagating cells (cancer stem cells) in
these tumors. In contrast to the stem-like (CD133+, multipotent, neurosphere-forming) cells
that have been shown to be important for propagation of other brain tumors (54, 55), we
have found that growth of ptc-associated medulloblastoma is dependent on GNP-like cells
that express the surface marker CD15 (49). Although a recent report suggested that long-
term culture of ptc+/− tumor cells in FGF-containing media can expand a rare population of
stem-like cells with tumorigenic potential (56), our demonstration that acute bFGF treatment
– either in vitro or in vivo – dramatically inhibits subsequent tumor growth raises questions
about the role of these cells in tumor maintenance and their importance as targets for
therapy. Although bFGF is likely to have different effects on different classes of brain
tumors (and could potentially enhance the growth of some tumor subtypes), at least for
Hedgehog pathway-associated medulloblastoma, it appears to be a potent inhibitor of tumor
growth.
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Hedgehog antagonists have recently moved into clinical trials for a variety of types of
cancer, and have begun to show some promise for treatment of medulloblastoma (57).
However, early reports also suggest that resistance to these antagonists can develop quite
readily (58). Therefore, it is critical to develop alternative approaches to targeting these
diseases. Although bFGF does not readily cross the blood-brain barrier (59), our results
suggest that intratumoral injection (perhaps aided by convection-enhanced delivery (60))
could be an effective mode of therapy. Small molecules that mimic the effects of bFGF
(61-63) might also be useful for overcoming the blood brain barrier. The fact that some
medulloblastoma cell lines are growth inhibited by bFGF (64, 65) suggests that our results




Math1-Cre transgenics (5, 6) were from David Rowitch at UCSF. FGFR1 conditional
knockout (Fgfr1F/F) mice (43) were obtained from Chuxia Deng at the National Institutes of
Health; FGFR2 conditional knockouts (Fgfr2F/F (44)) were provided by David Ornitz at
Washington University. FGFR4 germline knockouts (Fgfr4−/− (66)) were maintained on a
C57/BL6 background in our colony. NeuroD2-SmoA1 transgenic mice (32) were a gift from
James Olson, Fred Hutchinson Cancer Center. FGFR triple knockout (TKO) mice were
offspring of Fgfr1F/F; Fgfr2F/F; Fgfr4−/− x Fgfr1F/F; Fgfr2F/F; Fgfr4+/−; Math1-Cre+/− pairs.
ptc+/− mice (24) were bred in our colony. Animals were bred and maintained in the Cancer
Center Isolation Facility at Duke Medical Center.
Growth Factors
bFGF (Peprotech, Rocky Hill, NJ) was used at 25 ng/mL except where indicated. Shh
supernatant was generated by transfecting 293T cells with Shh-N expression plasmid (David
Robbins, Dartmouth Medical School, Hanover, NH) and harvesting supernatant for 3 days.
Supernatant was used at 20% final concentration.
Isolation and Culture of GNPs and Tumor cells
GNPs were isolated from 2 to 11-day-old mice as described in (50). Tumor cells were
isolated using a similar procedure from ptc+/− and NeuroD2-SmoA1 mice displaying signs
of medulloblastoma. For isolation of CD15+ and CD15− populations, tumor cells were
stained with anti-CD15 antibodies (clone MMA, BD Biosciences, San Jose, CA) and with
phycoerythrin-conjugated goat-anti-mouse IgM secondary antibodies (Jackson
ImmunoResearch, West Grove, PA), and then sorted using a BD FACSVantage flow
cytometer. Cells were cultured on poly-D-lysine (PDL)-coated plates in Neurobasal medium
containing 2% B27, 1 mM sodium pyruvate, 2 mM L-glutamine, and 1% Pen/Strep (all from
Invitrogen, Carlsbad, CA).
RNA Isolation and RT-PCR
RNA was isolated by using the RNAqueous kit (Ambion, Austin, TX). Lysates were treated
with DNA-free DNase treatment and removal reagents (Ambion), and RNA was quantitated
on a TD-700 fluorometer (Turner BioSystems, Sunnyvale, CA) by using RiboGreen
(Invitrogen). RT-PCR for fgfr1-4 was performed using primers described in (34). First-
strand cDNA was synthesized using equivalent amounts of total RNA (0.1-1 μg) in a 20-μl
reverse transcriptase reaction mixture (Invitrogen). PCR was performed using Platinium Taq
(Invitrogen) in a 25uL reaction followed by electrophoresis on a 1.5% agarose gel. Real-
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time PCR for gli1 was performed as described in (50). Sufu−/− MEFs were a generous gift
from Matthias Lauth and Rune Toftgard at the Karolinska Institute, Huddinge, Sweden.
Western Blotting
GNPs from P7 WT and FGFR TKO mice were cultured for 4 hours on PDL-coated plates in
Neurobasal media with no additives or with 25ng/mL bFGF. Cells were washed twice with
cold PBS and lysed in 200 μl RIPA buffer (0.5M Tris-HCl, pH 7.4, 1.5M NaCl, 2.5%
deoxycholic acid, 10% NP-40, 10mM EDTA) with protease and phosphatase inhibitor
cocktail (Thermo, Cat# 1861280) for 30 minutes on ice. Lysates were sonicated using an
ultrasonicator (Misonix) at amplitude 2 for 5 seconds, and then centrifuged at 13,000 rpm
for 10 min at 4°C. Protein concentrations were measured using a Bradford assay. Equal
amounts of protein were separated by 8% SDS polyacylamide gel electrophoresis (SDS-
PAGE) and transferred to nitrocellulose membranes (Invitrogen, Cat# LC2006). Membranes
were blocked with 5% BSA and then probed with anti-pERK and anti-total ERK (both from
Santa Cruz), and with IRDye680-labeled Goat anti-Mouse IgG antibodies (Li-Cor
Biosciences). All antibodies were diluted 1:3000 in Tris-buffered saline with 0.1%
Tween-20. Proteins were visualized using Li-Cor Odyssey Imager.
Proliferation Assays
For measurement of thymidine incorporation, GNPs and tumor cells were cultured in PDL-
coated 96-well plates at 2 × 105 cells per well. Growth factors were added at the beginning
of culture, and cells were incubated for 48 h before being pulsed with [methyl-3H]-
Thymidine (PerkinElmer, Fremont, CA). After 16 h, cells were harvested by using a Mach
IIIM Manual Harvester 96 (Tomtec, Hamden, CT), and incorporated radioactivity was
quantitated by using a Wallac MicroBeta microplate scintillation counter (PerkinElmer).
For cell cycle analysis, cells were cultured in PDL-coated plates as described above. After
48 hours, cells were fixed and permeabilized for 20 min in 100 μl of BD Cytofix/Cytoperm
Solution (BD Biosciences, San Jose, CA). Cells were then washed with 1 ml of BD Perm/
Wash Buffer (BD Biosciences) and resuspended in 20 μl of 7-Aminoactinomycin D (7-
AAD). 300 μl of FACS buffer (5% fetal bovine serum in PBS) was added to the cells, and
samples were analyzed on a FACScan Flow Cytometer (Becton Dickinson, Franklin Lakes,
NJ). Cell cycle profiles were analyzed using FlowJo software (TreeStar Inc., Ashland, OR).
Immunofluorescence Staining and Analysis
For staining of frozen tissue, brains were fixed in 4% paraformaldehyde, cryoprotected in
30% sucrose, embedded in Tissue-Tek OCT (Sakura Finetek, Torrance, CA) and sectioned
sagittally at a thickness of 12 μm. Sections were permeabilized with PBST (PBS + 0.1%
Triton X-100), blocked with PBST + 10% normal goat serum, and incubated with primary
antibodies specific for Ki67 (Abcam, Cambridge, MA) and NeuN (Millipore, Temecula,
CA) overnight at 4°C followed by Alexa Fluor 594-anti-rabbit and Alexa Fluor 488-anti-
mouse secondary antibodies (Molecular Probes, Eugene, OR) for 1 hr at room temperature.
Sections were counterstained with DAPI (Molecular Probes) and mounted in Fluoromount-
G (Southern Biotechnology Associates, Birmingham, AL). Tiled images were taken using a
Zeiss LSM 510 inverted confocal microscope and related software at the Duke Light
Microscopy Core Facility.
To measure apoptosis, GNPs or tumor cells were fixed in 4% PFA and stained with
antibodies against cleaved caspase-3 (Cell Signaling Technology) and goat anti-rabbit IgG
secondary antibodies (Jackson Immunoresearch). Following staining, immunofluorescent
pictures of six randomly-selected fields were taken from each well of cultured cells using a
Zeiss LSM 510 inverted confocal microscope and related software at the Duke Light
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Microscopy Core Facility. Cells were counted for positive cleaved caspase-3 and DAPI
respectively. The ratio of cleaved caspase-3 to DAPI staining was determined for each
culture condition and compared.
Stereotaxic Implantation and in vivo Treatment of Tumor Cells
Tumor cells from Math1-GFP; ptc+/− mice were transplanted into SCID-beige mice as
described in (49). For bFGF pretreatment studies, animals were followed for 6 months and
sacrificed when they developed symptoms of medulloblastoma (ataxia, lethargy,
hydrocephaly). For in vivo bFGF treatment studies, PBS or bFGF (80ng/ml, 2.5 μl) was
injected into the transplant site 8-12 days after transplantation, and again 3-5 days later.
When any of the mice in a cohort exhibited symptoms, the entire cohort was sacrificed.
Animals were perfused with 4% paraformaldehyde and brains were imaged by whole mount
microscopy using a Leica MC 16 FA microscope, Micropublisher 5.0 RTV camera and
QCapture software (QImaging, Surray, BC). Brains were then frozen in OCT, sectioned
from end to end, and stained with hematoxylin and eosin or with DAPI as described above.
Sections were examined for the presence of GFP+ tumor cells, and lateral tumor extension
was calculated by counting the number of sections containing such cells and multiplying by
the thickness of these sections.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. bFGF inhibits proliferation of GNPs throughout postnatal development
GNPs were isolated from P2 (A), P4 (B), P7 (C), or P11 (D) mice and cultured in media
with no added factors (Control) or 20% Shh supernatant ± bFGF (25 ng/mL) for 48 hrs.
Cells were pulsed with tritiated thymidine (3H-Td) and cultured for 16hr before being
assayed for thymidine incorporation. Data represent means of triplicate samples ± SEM.
Differences in proliferation between Shh and Shh+bFGF were statistically significant (p <
0.0001 based on Student’s t-test) at P4, P7 and P11; at P2, the difference was 2.7-fold, but
did not reach significance (p = 0.09).
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Figure 2. FGF-mediated inhibition of proliferation requires FGFR1
(A) Expression of FGFR isoforms in GNPs. RNA was isolated from FACS-sorted Math1-
GFP+ cells at P7 and FGFR expression was assessed by PCR using isoform-specific
primers. RT-PCR for beta 2-microglobulin was performed on each sample in parallel to
control for variability among samples. (B-D) GNPs from P7 Math1-Cre;FGFR1F/F (FGFR1
KO, panel B), Math1-Cre;FGFR2F/F (FGFR2 KO, panel C) or FGFR4−/− mice (FGFR4 KO,
panel D) were cultured in media containing no added factors (Control) or Shh ± bFGF for
48hrs. Cells were pulsed with 3H-Td and cultured for 16hr before being assayed for
thymidine incorporation. Data represent means of triplicate samples ± SEM. Differences in
proliferation between Shh and Shh+bFGF were statistically significant (p < 0.002 based on
Student’s t-test) for all genotypes except FGFR1 KO mice; in those animals (panel B, black
bars), proliferation in response to Shh+bFGF was not significantly different from
proliferation in response to Shh alone (p = 0.66).
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Figure 3. Loss of FGF signaling does not alter GNP growth or differentiation
(A-B) Mid-sagittal sections from cerebella of P7 Math1-Cre;FGFR1F/F mice (FGFR1 KO,
B) and littermate controls (A) were stained with anti-Ki67 (red) and anti-NeuN (green)
antibodies. (C-D) Mid-sagittal sections from P7 triple knockout (Math1-Cre; FGFR1F/F;
FGFR2F/F; FGFR4−/−) mice (TKO, D) and control (C) cerebella were stained with anti-Ki67
antibodies (red) and counterstained with DAPI. Note the similarity in the thickness of the
EGL and in the numbers of proliferating (Ki67+) cells in mutant and WT mice.
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Figure 4. Exposure to bFGF prevents engraftment of medulloblastoma cells
(A) bFGF inhibits proliferation of tumor-propagating cells. Tumor cells from ptc+/− mice
were left unsorted or FACS-sorted into CD15+ and CD15− populations, and then cultured in
media with no added factors (Control) or bFGF for 48 hrs. Cells were pulsed with 3H-Td
and cultured for an additional 16 hrs before being assayed for thymidine incorporation. Data
represent means of triplicate samples ± SEM. Differences between control and bFGF-treated
cells were significant for all populations (p < 0.0001 based on unpaired Student’s t-tests).
(B) ptc+/− tumor cells were cultured in the presence or absence of bFGF for 24 hrs and then
transplanted into SCID-beige recipient mice. Mice were sacrificed when they displayed
symptoms. (C) Survival of animals implanted with Control or bFGF-treated tumor cells.
None of the mice receiving bFGF-treated tumor cells developed medulloblastoma, whereas
Emmenegger et al. Page 17













13/14 (93%) of mice receiving Control tumor cells developed medulloblastoma. Survival
curves were significantly different (p < 0.0001) based on Log-Rank (Mantel-Cox) test.
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Figure 5. bFGF inhibits medulloblastoma growth in vivo
(A) Tumor cells were isolated from Math1-GFP; ptc+/− mice and immediately implanted
into the cerebellum of SCID-beige mice. Eight to twelve days after transplantation, animals
were injected with PBS or bFGF, and then monitored for symptoms of medulloblastoma. (B-
C) Representative whole-mount pictures illustrating the presence of large GFP+ (green)
tumors in Control (PBS-treated) mice (B) and the relatively small lesions detected in bFGF-
treated mice (C). (D-G) Cryosections stained with DAPI (blue) showing tumors (indicated
by GFP fluorescence, green) observed in representative Control (D, F) and bFGF-treated (E,
G) mice. (H) Quantitative analysis of tumor size in three cohorts of mice (cohorts, consisting
of animals transplanted with tumor cells from a separate Math1-GFP; ptc+/− donor, are
designated by triangles, squares, or diamonds respectively). Lateral extension of each tumor
was calculated as described in Materials and Methods. Lateral tumor extension was
significantly different in bFGF-treated mice (mean = 0.7 mm) vs. Control mice (mean = 6.0
mm), p < 0.0001 determined by unpaired Student’s t-test.
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